Results 111 to 120 of about 1,075,882 (382)

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)

Indian Journal of Anaesthesia, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for primary peritoneal malignancies or peritoneal spread of malignant neoplasm is being done at many centres worldwide.
S. Solanki, S. Mukherjee, V. Agarwal, R. Thota, Kalpana Balakrishnan, S. Shah, Neha Desai, R. Garg, R. Ambulkar, N. Bhorkar, Viplab Patro, S. Sinukumar, Meenakshi V Venketeswaran, Malini Joshi, R. H. Chikkalingegowda, V. Gottumukkala, P. Owusu-Agyemang, A. Saklani, S. Mehta, R. Seshadri, J. Bell, S. Bhatnagar, J. Divatia   +22 more
semanticscholar   +1 more source

Single‐Cell Transcriptome Atlas Reveals the Underlying Mechanism of Kynurenic Acid in the Regulation of Tumor Immune Microenvironment in Glioblastoma

Advanced Science, EarlyView.
KYNA regulates the tumor immune microenvironment in glioblastoma. KYNA reprograms the balance between T cell exhaustion and activation to suppress glioblastoma progression through inhibiting exhaustion‐associated markers (such as PD‐1, LAG3, and TOX) and enhancing immune activation and cytotoxicity markers including granzymes GZMA and GZMB.
Di Chen, Liming Sun, Jiajun Chen, Zi Ye, Xuqiang Zhu, Hongjiang Li, Lixin Wu, Guohua Zhao, Qinghao Zhang, Guangyi Jiang, Yuchen Ji, Yake Xue, Hongwei Li, Ruokun Chen, Hongwei Zheng, Rong Zeng, Dongming Yan, Yong Zhang, Xueyuan Li, Jing Yan   +19 more
wiley   +1 more source

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy plus Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Malignant Ascites

Journal of Medical Sciences
Background Patients with gastric cancer (GC) and malignant ascites (MA) usually have poor outcomes and a high risk of recurrence and mortality, even after curative gastrectomy or chemotherapy.
Hsing-Wei Yu, Guo-Shiou Liao, Ting-Ying Lee, De-Chuan Chan   +3 more
doaj   +1 more source

HE4 in the differential diagnosis of ovarian masses [PDF]

, 2015
Ovarian masses, a common finding among pre- and post-menopausal women, can be benign or malignant. Ovarian cancer is the leading cause of death from gynecologic malignancy among women living in industrialized countries.
ANASTASI, Emanuela, ANGELONI, Antonio, Flavia Longo, MANGANARO, Lucia, PORPORA, Maria Grazia, Teresa Granato   +5 more
core   +1 more source

TREM2 Drives Neutrophil Extracellular Traps‐Induced Dendritic Cell Maturation and Contributes to Lupus Progression

Advanced Science, EarlyView.
TREM2 recognizes NETs‐derived MPO to promote DC maturation and antigen presentation, thereby exacerbating the autoimmune response in SLE. Mechanistically, TREM2 activation triggers the DAP12/SYK/ERK cascade and enhances NETs internalization by DCs, which in turn activates the cGAS/STING signaling pathway.
Jingxian Shu, Jiabi Liang, Linda Zeng, Shuping Zhong, Xueling Fang, Yating Xu, Yongjian Wu, Xi Huang   +7 more
wiley   +1 more source

Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models

Frontiers in Oncology
IntroductionIntraperitoneal chemotherapy for ovarian cancer treatment has controversial benefits as most methodologies are associated with significant morbidity.
Marcelo Simonsen, Marcelo Simonsen, Rossana Verónica Mendoza López, Simone Maistro, Lucas Takeshi Ikeoka, Glaucia Fernanda de Lima Pereira, Ademar Benévolo Lugão, José Carlos Sadalla, Maria Lúcia Hirata Katayama, Maria Aparecida Azevedo Koike Folgueira   +9 more
doaj   +1 more source

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up [PDF]

, 2021
Parisa Malekzadeh, Meghan L. Good, Marybeth S. Hughes   +2 more
openalex   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.

The Lancet Oncology, 2021
F. Quénet, D. Elias, L. Roca, D. Goéré, L. Ghouti, M. Pocard, O. Facy, C. Arvieux, G. Lorimier, D. Pezet, F. Marchal, V. Loi, P. Meeus, B. Juzyna, H. De forges, J. Paineau, O. Glehen   +16 more
semanticscholar   +1 more source

Wedelolactone, a Novel TLR2 Agonist, Promotes Neutrophil Differentiation and Ameliorates Neutropenia: A Multi‐Omics Approach to Unravel the Mechanism

Advanced Science, EarlyView.
Wedelolactone (WED), a natural TLR2 agonist, promotes neutrophil differentiation and enhances bactericidal function, offering a potential therapeutic strategy for neutropenia. Using a multi‐omics approach, this study reveals that WED activates the TLR2/MEK/ERK pathway, upregulating key transcription factors (PU.1, CEBPβ) to drive neutrophil development.
Long Wang, Zhichao Li, Tianci Hu, Qinyao Li, Linwei Zhang, Xinyue Mei, Xiao Qi, Sheng Liu, Weijie Kong, Jiesi Luo, Anguo Wu, Feihong Huang, Sirui Li, Shuang Dai, Chunxiang Zhang, Rong Li, Jianming Wu   +16 more
wiley   +1 more source